DELRAY BEACH, Fla., June 2, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Cardiac Marker Testing Market is projected to grow from about USD 5.54 billion in 2026 to USD 9.06 billion by 2031, at a CAGR of 10.3%.
Browse 457 market data Tables and 55 Figures spread through 372 Pages and in-depth TOC on 'Cardiac Marker Testing Market - Global Forecast to 2031'
Cardiac Marker Testing Market Size & Forecast:
- Market Size Available for Years: 2025-2031
- 2026 Market Size: USD 5.54 billion
- 2031 Projected Market Size: USD 9.06 billion
- CAGR (2026-2031): 10.3%
Cardiac Marker Testing Market Trends & Insights:
- The reagents & kits segment is expected to register the highest growth rate with 11%.
- Troponin I & T leads the market with a share of 40.3% in 2025.
- Lab tests accounted for the largest market share of 74.7% in 2025.
- Multiplex assay to grow at the highest rate of 11.6%.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447
The main drivers of the market are the growing use of point-of-care testing solutions and the rising demand for rapid test results in emergency situations. The demand for cardiac marker testing is also fueled by the increasing geriatric population and the prevalence of lifestyle diseases such as obesity and diabetes. The increasing focus on decentralized healthcare systems is also a major driver of the cardiac marker testing market. The growing focus on developing new technologies for multiplex biomarker testing is also a key driver of the cardiac marker testing market.
Moreover, market growth depends significantly on technological advancements that provide substantial benefits to the industry. The creation of highly sensitive cardiac biomarker assays, the use of laboratory automation, and the integration of digital health and data management systems have improved diagnostic efficiency and decision-making. Healthcare providers and diagnostic companies can utilize more reliable and efficient testing solutions due to industry innovations, including advanced immunoassay technologies, multiplex testing, and assay specificity for early detection. Additionally, testing solutions have been validated to help manage complex clinical conditions and accurately assess patients from diverse populations.
In the cardiac marker testing market, the reagents & kits segment accounted for the larger share within the product segment in 2026.
This market is segmented into reagents/kits and instruments. Factors that drive the growth of the reagents/kits segment include the growing demand for advanced diagnostic solutions, the growing incidence of cardiovascular diseases, and the need to obtain quick and accurate results. Moreover, the expansion of diagnostic labs and infrastructure, combined with the constant improvement in the quality of automated testing equipment, is also fueling the demand for cardiac marker testing instruments.
Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=64885447
In the cardiac marker testing market, the point-of-care testing segment is projected to register the highest growth during the forecast period.
The end users of the cardiac marker testing market include diagnostic labs, academic institutes, and point-of-care testing. The point-of-care testing segment is witnessing a strong growth trend, and this can be attributed to a number of factors, such as the rising need to achieve quick results in emergency and critical care settings. The increasing incidence of CVD and the need to achieve quick decision-making in patient care settings have led to a number of healthcare providers adopting point-of-care testing solutions for cardiac testing. The increased emphasis on decentralized patient care and the need to improve patient outcomes through quick diagnosis also contribute to the growth of point-of-care testing solutions for cardiac markers.
North America dominated the cardiac marker testing market in 2026.
The cardiac marker testing market segments are classified into five regions: Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa. North America accounted for the highest market share in the cardiac marker testing market in 2025. The market in this region is growing due to its healthcare infrastructure, high incidence rate of cardiovascular diseases, and the increased number of diagnostic tests performed in this region. High demand for cardiac marker testing in this region is due to the presence of high-end diagnostic centers and hospitals, along with stringent regulatory conditions for diagnostic accuracy, quality, and early detection of diseases.
Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64885447
Top Companies in Cardiac Marker Testing Market:
The Top Companies in Cardiac Marker Testing Market include Siemens (Germany), Roche Hoffmann (Switzerland), Danaher (US), Laboratories Abbott (US), Thermo Scientific (US), BD (US), Bio-Rad (US), Revvity (US), DiaSorin SPA (Italy), and Quidel Corporation (US).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Related Reports:
Lateral Flow Assays Market - Global Forecast to 2030
In Vitro Diagnostics Market - Global Forecast to 2030
Point of Care Diagnostics Market - Global Forecast to 2029
Biomarkers Market - Global Forecast to 2030
Cardiac Monitoring and Cardiac Rhythm Management Devices Market - Global Forecast to 2031
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cardiac-marker-testing-market-worth-9-06-billion-by-2031--marketsandmarkets-302788176.html
